Urea cycle disorders US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Urea cycle disorders. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Urea cycle disorders US Medical PG Question 1: A 3-week old boy is brought to the physician for the evaluation of lethargy, recurrent vomiting, and poor weight gain since birth. Physical examination shows decreased skin turgor and a bulging frontal fontanelle. Serum studies show an ammonia concentration of 170 μmol/L (N < 30) and low serum citrulline levels. The oral intake of which of the following nutrients should be restricted in this patient?
- A. Gluten
- B. Lactose
- C. Fructose
- D. Protein (Correct Answer)
- E. Vitamin A
Urea cycle disorders Explanation: ***Protein***
- Elevated **ammonia** and low **citrulline** levels indicate a **urea cycle disorder**, which impairs the body's ability to excrete nitrogenous waste from protein metabolism.
- Restricting **protein intake** limits the production of ammonia, thereby reducing the toxic burden on the system and preventing further neurological damage.
*Gluten*
- **Gluten restriction** is primarily indicated for **celiac disease**, which presents with gastrointestinal symptoms like diarrhea, malabsorption, and poor weight gain, but not directly with hyperammonemia or urea cycle dysfunction.
- While malabsorption can cause poor weight gain, the specific metabolic derangements here point away from celiac disease.
*Lactose*
- **Lactose intolerance** or **galactosemia** would necessitate **lactose restriction**. Symptoms usually include vomiting, diarrhea, and failure to thrive, but they do not typically present with the extreme hyperammonemia seen here.
- Galactosemia specifically would show elevated galactose and galactose-1-phosphate, not ammonia.
*Fructose*
- **Hereditary fructose intolerance** requires **fructose restriction**. It generally presents with vomiting, hypoglycemia, and liver dysfunction (jaundice, hepatomegaly) upon exposure to fructose, not primarily with hyperammonemia.
- The metabolic pathway for fructose metabolism does not directly generate ammonia in the quantities seen with urea cycle disorders.
*Vitamin A*
- **Vitamin A restriction** is not a primary treatment for any known inborn error of metabolism or hyperammonemia.
- While deficiencies or toxicities of vitamins can occur, they do not present with the specific metabolic profile described (high ammonia, low citrulline).
Urea cycle disorders US Medical PG Question 2: After being warned by the locals not to consume the freshwater, a group of American backpackers set off on a week-long hike into a region of the Ecuadorean Amazon forest known for large gold mines. The group of hikers stopped near a small stream and used the water they filtered from the stream to make dinner. Within the next half hour, the hikers began to experience headaches, vertigo, visual disturbances, confusion, tachycardia, and altered levels of consciousness. Which of the following enzymes was most likely inhibited in this group of hikers?
- A. NADH dehydrogenase
- B. ATP synthase
- C. Cytochrome c oxidase (Correct Answer)
- D. Cytochrome bc1 complex
- E. Succinate dehydrogenase
Urea cycle disorders Explanation: ***Cytochrome c oxidase***
- The symptoms described (headaches, vertigo, visual disturbances, confusion, tachycardia, altered consciousness occurring within 30 minutes) are characteristic of **acute cyanide poisoning**.
- **Cyanide** is commonly found in water near **gold mining operations**, where it is used in the gold extraction process and can contaminate local water sources.
- **Cyanide** is a potent inhibitor of **cytochrome c oxidase** (Complex IV) in the electron transport chain, binding to the heme iron (Fe³⁺) and preventing oxygen utilization, leading to **histotoxic hypoxia**.
- This results in cellular energy failure, particularly affecting high-energy-demand organs like the brain and heart, explaining the acute neurological and cardiovascular symptoms.
*NADH dehydrogenase*
- While NADH dehydrogenase (Complex I) is a component of the electron transport chain, it is not the primary target of **cyanide poisoning**.
- Inhibitors of Complex I include rotenone and barbiturates, which cause different clinical presentations and do not produce the rapid onset of symptoms seen with cyanide.
*ATP synthase*
- **ATP synthase** (Complex V) synthesizes ATP using the proton gradient, but it is not directly inhibited by **cyanide**.
- Inhibitors of ATP synthase, such as oligomycin, prevent ATP synthesis by blocking the enzyme directly, whereas cyanide acts upstream at Complex IV.
*Cytochrome bc1 complex*
- The **cytochrome bc1 complex** (Complex III) is involved in electron transfer and proton pumping, but it is not the primary enzyme inhibited by **cyanide**.
- Inhibitors of Complex III include antimycin A, which would disrupt the electron transport chain but do not cause the characteristic rapid-onset symptoms of cyanide poisoning.
*Succinate dehydrogenase*
- **Succinate dehydrogenase** (Complex II) participates in both the citric acid cycle and the electron transport chain, but it is not targeted by **cyanide**.
- Inhibitors of Complex II, such as malonate, competitively block succinate oxidation but do not produce the acute systemic toxicity characteristic of cyanide poisoning.
Urea cycle disorders US Medical PG Question 3: A 2-day-old male is seen in the newborn nursery for repeated emesis and lethargy. He was born at 39 weeks to a 24-year-old mother following an uncomplicated pregnancy and birth. He has been breastfeeding every 2 hours and has 10 wet diapers per day. His father has a history of beta-thalassemia minor. Laboratory results are as follows:
Hemoglobin: 12 g/dL
Platelet count: 200,000/mm³
Mean corpuscular volume: 95 µm³
Reticulocyte count: 0.5%
Leukocyte count: 5,000/mm³ with normal differential
Serum:
Na+: 134 mEq/L
Cl-: 100 mEq/L
K+: 3.3 mEq/L
HCO3-: 24 mEq/L
Urea nitrogen: 1 mg/dL
Creatinine: 0.6 mg/dL
Ammonia: 150 µmol/L (normal: 50-80 µmol/L)
Which of the following is the most likely diagnosis?
- A. Phenylketonuria
- B. Orotic aciduria
- C. Alkaptonuria
- D. Ornithine transcarbamylase deficiency (Correct Answer)
- E. Beta-thalassemia minor
Urea cycle disorders Explanation: ***Ornithine transcarbamylase deficiency***
- The combination of **lethargy**, vomiting (emesis), and **significantly elevated ammonia levels** in a neonate strongly points to a **urea cycle disorder**, with ornithine transcarbamylase (OTC) deficiency being the most common.
- This X-linked disorder leads to a buildup of ammonia due to the inability to convert carbamoyl phosphate and ornithine into citrulline, a crucial step in the urea cycle.
*Phenylketonuria*
- Characterized by the inability to metabolize **phenylalanine**, leading to its accumulation and neurological damage if untreated.
- Typically presents with developmental delay, seizures, and a musty odor, not acute hyperammonemia and vomiting in the neonatal period.
*Orotic aciduria*
- A rare metabolic disorder caused by a defect in **pyrimidine synthesis**, leading to accumulation of **orotic acid**.
- Presents with megaloblastic anemia, developmental delay, and failure to thrive, but not typically with severe neonatal hyperammonemia.
*Alkaptonuria*
- An autosomal recessive disorder of **tyrosine metabolism** where homogentisic acid oxidase is deficient, leading to a buildup of **homogentisic acid**.
- Characterized by dark urine when exposed to air, ochronosis (bluish-black pigmentation of cartilage), and early-onset osteoarthritis; it does not cause acute neonatal illness with hyperammonemia.
*Beta-thalassemia minor*
- This is an **inherited blood disorder** causing mild anemia, often asymptomatic, due to reduced or absent beta-globin chain production.
- While the father has this condition, the infant's symptoms of lethargy, vomiting, and hyperammonemia are **not consistent** with beta-thalassemia minor.
Urea cycle disorders US Medical PG Question 4: A 2-week-old boy presents to the emergency department because of unusual irritability and lethargy. The patient is admitted to the pediatric intensive care unit and minutes later develops metabolic encephalopathy. This progressed to a coma, followed by death before any laboratory tests are completed. The infant was born at home via vaginal delivery at 39 weeks' of gestation. His mother says that the symptoms started since the infant was 4-days-old, but since he only seemed ‘tired’, she decided not to seek medical attention. Further testing during autopsy shows hyperammonemia, low citrulline, and increased orotic acid. Which of the following enzymes is most likely deficient in this patient?
- A. Branched-chain alpha-ketoacid dehydrogenase
- B. Propionyl-CoA carboxylase
- C. Homogentisic acid dioxygenase
- D. Ornithine transcarbamylase (Correct Answer)
- E. Cystathionine beta-synthase
Urea cycle disorders Explanation: **Ornithine transcarbamylase**
- **Hyperammonemia**, **low citrulline**, and **increased orotic acid** are classic findings in **Ornithine Transcarbamylase (OTC) deficiency**. OTC is an X-linked urea cycle disorder.
- The rapid progression to **metabolic encephalopathy** and death in a neonate with these laboratory findings is highly characteristic of severe OTC deficiency, often presenting in the first few days of life.
*Branched-chain alpha-ketoacid dehydrogenase*
- Deficiency of this enzyme causes **Maple Syrup Urine Disease**, characterized by elevated **branched-chain amino acids** and their corresponding ketoacids in blood and urine.
- While it can cause neurological symptoms, it does not typically present with the specific constellation of **hyperammonemia**, low citrulline, and high orotic acid.
*Propionyl-CoA carboxylase*
- Deficiency of this enzyme leads to **Propionic acidemia**, a type of organic acidemia, characterized by **propionic acid accumulation** and often **metabolic acidosis**, ketosis, and hyperammonemia.
- However, it would not typically cause **low citrulline** or isolated **elevated orotic acid** as seen in urea cycle disorders.
*Homogentisic acid dioxygenase*
- Deficiency of this enzyme causes **Alkaptonuria**, an inborn error of metabolism characterized by the accumulation of **homogentisic acid**.
- This condition is usually benign in infancy, with symptoms appearing later in life such as **dark urine** on standing and **ochronosis** (darkening of cartilage). It does not present with acute hyperammonemia or metabolic encephalopathy.
*Cystathionine beta-synthase*
- Deficiency of this enzyme causes **homocystinuria**, an inborn error of methionine metabolism, leading to elevated **homocysteine** and methionine.
- Clinical features include **ectopia lentis**, skeletal abnormalities, and intellectual disability, but not usually acute neonatal hyperammonemia or the specific findings of low citrulline and high orotic acid.
Urea cycle disorders US Medical PG Question 5: A newborn boy develops projectile vomiting 48 hours after delivery. He is found to be lethargic, with poor muscle tone, and is hyperventilating. Within hours, he suffers important neurological deterioration, leading to seizures, coma, and, ultimately, death. An autopsy is performed and the pathology team makes a diagnosis of a rare genetic disorder that leads to low levels of N-acetylglutamate. Which of the following enzymes would be secondarily affected by this process?
- A. Argininosuccinate lyase
- B. Carbamoyl phosphate synthetase I (Correct Answer)
- C. Argininosuccinate synthetase
- D. Ornithine transcarbamylase
- E. Arginase
Urea cycle disorders Explanation: ***Carbamoyl phosphate synthetase I***
- **N-acetylglutamate** is an **obligate activator** for **Carbamoyl phosphate synthetase I (CPS I)**, the rate-limiting enzyme of the **urea cycle**. Low levels of N-acetylglutamate directly impair CPS I activity.
- Reduced CPS I activity leads to a severe **urea cycle disorder**, causing **hyperammonemia**, which manifests with lethargy, poor muscle tone, hyperventilation, neurological deterioration, seizures, coma, and death in newborns.
*Argininosuccinate lyase*
- This enzyme is involved downstream in the **urea cycle**, catalyzing the cleavage of **argininosuccinate** into **arginine** and **fumarate**.
- Its activity is not directly regulated by **N-acetylglutamate**, so it would not be secondarily affected in the same manner as CPS I.
*Argininosuccinate synthetase*
- This enzyme acts after CPS I and ornithine transcarbamylase in the **urea cycle**, synthesizing **argininosuccinate** from **citrulline** and **aspartate**.
- Its function is independent of **N-acetylglutamate** levels, making it unlikely to be secondarily affected.
*Ornithine transcarbamylase*
- This enzyme catalyzes the second step of the **urea cycle**, forming **citrulline** from **ornithine** and **carbamoyl phosphate**.
- While essential for the urea cycle, its activity is not directly modulated by **N-acetylglutamate**; rather, it depends on the availability of carbamoyl phosphate produced by CPS I.
*Arginase*
- This is the final enzyme in the **urea cycle**, converting **arginine** to **ornithine** and **urea**.
- Its activity is not directly or indirectly regulated by **N-acetylglutamate**, nor is it the enzyme primarily affected in this presentation.
Urea cycle disorders US Medical PG Question 6: A 65-year old man comes to the emergency department because of altered mental status for 1 day. He has had headaches, severe nausea, vomiting, and diarrhea for 2 days. He has a history of hypertension, insomnia, and bipolar disorder. His medications include lisinopril, fluoxetine, atorvastatin, lithium, olanzapine, and alprazolam. His temperature is 37.2 °C (99.0 °F), pulse is 90/min, respirations are 22/min, and blood pressure is 102/68 mm Hg. He is somnolent and confused. His mucous membranes are dry. Neurological examination shows dysarthria, decreased muscle strength throughout, and a coarse tremor of the hands bilaterally. The remainder of the examination shows no abnormalities. In addition to IV hydration and electrolyte supplementation, which of the following is the next best step in management?
- A. Bowel irrigation
- B. Intravenous diazepam
- C. Oral cyproheptadine
- D. Intravenous dantrolene
- E. Hemodialysis (Correct Answer)
Urea cycle disorders Explanation: ***Hemodialysis***
- This patient presents with symptoms consistent with **severe lithium toxicity** (altered mental status, somnolence, confusion, dysarthria, decreased muscle strength, coarse tremor) likely exacerbated by dehydration due to nausea, vomiting, and diarrhea.
- **Hemodialysis** is indicated for severe lithium toxicity, especially when plasma lithium levels are very high (>4.0 mEq/L), there are signs of cerebellar toxicity or seizures, or if renal impairment prevents adequate lithium excretion.
*Bowel irrigation*
- **Whole-bowel irrigation** is primarily used for large ingestions of sustained-release or enteric-coated medications, or substances not adsorbed by activated charcoal.
- It is generally *not* effective for removing lithium, as lithium is rapidly and completely absorbed from the gastrointestinal tract.
*Intravenous diazepam*
- **Benzodiazepines** like diazepam are useful for managing seizures or severe agitation associated with drug toxicities but do not address the underlying cause of lithium toxicity by removing the drug from the body.
- While agitation and seizures might occur in severe lithium toxicity, the primary initial step in severe cases is to remove the excess lithium.
*Oral cyproheptadine*
- **Cyproheptadine** is an antihistamine with antiserotonergic properties, used in the treatment of **serotonin syndrome**.
- This patient's clinical presentation is classic for **lithium toxicity**, not serotonin syndrome, although fluoxetine can contribute to serotonin syndrome, the tremor and neurological picture coupled with lithium use points to lithium toxicity.
*Intravenous dantrolene*
- **Dantrolene** is a muscle relaxant primarily used for conditions like **neuroleptic malignant syndrome** (NMS) or malignant hyperthermia due to its direct action on skeletal muscle.
- It is not indicated for treating the central nervous system effects or removal of lithium in lithium toxicity.
Urea cycle disorders US Medical PG Question 7: A 2-day-old male infant is brought to the emergency department by ambulance after his parents noticed that he was convulsing and unresponsive. He was born at home and appeared well initially; however, within 24 hours he became increasingly irritable and lethargic. Furthermore, he stopped feeding and began to experience worsening tachypnea. This continued for about 6 hours, at which point his parents noticed the convulsions and called for an ambulance. Laboratories are obtained with the following results:
Orotic acid: 9.2 mmol/mol creatinine (normal: 1.4-5.3 mmol/mol creatinine)
Ammonia: 135 µmol/L (normal: < 50 µmol/L)
Citrulline: 2 µmol/L (normal: 10-45 µmol/L)
Which of the following treatments would most likely be beneficial to this patient?
- A. Galactose avoidance
- B. Aspartame avoidance
- C. Benzoate administration (Correct Answer)
- D. Uridine administration
- E. Fructose avoidance
Urea cycle disorders Explanation: ***Benzoate administration***
- This patient presents with hyperammonemia (135 µmol/L), elevated orotic acid (9.2 mmol/mol creatinine), and **low citrulline (2 µmol/L)**, which is the classic triad for **ornithine transcarbamylase (OTC) deficiency**.
- The low citrulline distinguishes OTC deficiency from other urea cycle defects, while elevated orotic acid results from accumulation of carbamoyl phosphate that gets shunted into pyrimidine synthesis.
- **Sodium benzoate** is a nitrogen scavenger that conjugates with glycine to form hippurate, which is excreted renally, providing an alternative pathway for nitrogen disposal and reducing toxic ammonia levels.
- This is a life-saving acute treatment for hyperammonemia in urea cycle disorders.
*Galactose avoidance*
- This is the treatment for **galactosemia**, a disorder of galactose metabolism caused by galactose-1-phosphate uridyltransferase deficiency.
- Galactosemia presents with hepatomegaly, jaundice, cataracts, intellectual disability, and hypoglycemia after milk feeding.
- The patient's hyperammonemia and elevated orotic acid pattern is incompatible with galactosemia.
*Aspartame avoidance*
- This is relevant for **phenylketonuria (PKU)** dietary management, as aspartame contains phenylalanine.
- PKU presents with developmental delay, intellectual disability, musty odor, and eczema, with elevated phenylalanine levels.
- Ammonia and orotic acid are normal in PKU, making this diagnosis inconsistent with the lab findings.
*Uridine administration*
- **Uridine** treats **hereditary orotic aciduria** (UMP synthase deficiency), which presents with megaloblastic anemia, growth retardation, and developmental delays.
- While orotic acid is elevated in both conditions, hereditary orotic aciduria has **normal ammonia** and the primary pathology is impaired pyrimidine synthesis, not ammonia disposal.
- This patient's life-threatening hyperammonemia requires immediate nitrogen scavenging, which uridine does not provide.
*Fructose avoidance*
- This treats **hereditary fructose intolerance** (aldolase B deficiency), which causes hypoglycemia, vomiting, hepatomegaly, and jaundice after fructose ingestion.
- The presentation is triggered by dietary fructose exposure and does not cause hyperammonemia or elevated orotic acid.
- The patient's metabolic profile is inconsistent with a fructose metabolism disorder.
Urea cycle disorders US Medical PG Question 8: A 20-year-old male presents with confusion, asterixis, and odd behavior. Very early in the morning, his mother found him urinating on the floor of his bedroom. A detailed history taken from the mother revealed that he has been a vegetarian his entire life but decided to "bulk up" by working out and consuming whey protein several times a day. A blood test revealed increased levels of ammonia and orotic acid but a decreased BUN. The patient began hemodialysis and was given oral sodium benzoate and phenylbutyrate, which improved his condition. Gene therapy of the enzyme producing which product would correct his condition?
- A. Citrulline (Correct Answer)
- B. Fructose-1-phosphate
- C. Homocysteine
- D. Phenylalanine
- E. Uridine monophosphate
Urea cycle disorders Explanation: ***Citrulline***
- The clinical presentation (confusion, asterixis, bizarre behavior, high ammonia, low BUN, high orotic acid, improvement with sodium benzoate and phenylbutyrate) is classic for a **urea cycle disorder**, specifically **ornithine transcarbamylase (OTC) deficiency**.
- OTC catalyzes the conversion of ornithine and carbamoyl phosphate to citrulline. A deficiency in OTC leads to a buildup of carbamoyl phosphate, which is then shunted to the pyrimidine synthesis pathway, leading to increased orotic acid. Therefore, gene therapy for the enzyme producing citrulline (OTC) would address the underlying defect.
*Fructose-1-phosphate*
- This is an intermediate in **fructose metabolism**. Disorders related to this, such as **hereditary fructose intolerance**, are not associated with hyperammonemia or orotic aciduria in this manner.
- Symptoms typically involve hypoglycemia, vomiting, and liver dysfunction upon fructose ingestion.
*Homocysteine*
- Elevated homocysteine levels are characteristic of **homocystinuria**, which is due to defects in methionine metabolism, often involving **cystathionine beta-synthase** or enzymes in the folate/B12 pathways.
- Homocystinuria presents with developmental delay, skeletal abnormalities, and thromboembolic events, distinct from the patient's symptoms.
*Phenylalanine*
- Elevated phenylalanine is the hallmark of **phenylketonuria (PKU)**, an inherited disorder of amino acid metabolism where the body cannot process **phenylalanine**.
- PKU primarily causes neurological issues if untreated, but not typically hyperammonemia or orotic aciduria.
*Uridine monophosphate*
- While orotic acid is a precursor to uridine monophosphate in pyrimidine synthesis, a direct gene therapy for the enzyme producing uridine monophosphate is not the primary intervention for the underlying urea cycle disorder.
- The high orotic acid is a consequence of the urea cycle blockade, not the primary defect itself.
Urea cycle disorders US Medical PG Question 9: A 4-day-old male newborn delivered at 39 weeks' gestation is evaluated because of poor feeding, recurrent vomiting, and lethargy. Physical examination shows tachypnea with subcostal retractions. An enzyme assay performed on a liver biopsy specimen shows decreased activity of carbamoyl phosphate synthetase I. This enzyme plays an important role in the breakdown and excretion of amino groups that result from protein digestion. Which of the following is an immediate substrate for the synthesis of the molecule needed for the excretion of amino groups?
- A. N-acetylglutamate
- B. Homocysteine
- C. Phenylalanine
- D. Valine
- E. Aspartate (Correct Answer)
Urea cycle disorders Explanation: ***Aspartate***
- The question describes a case of **carbamoyl phosphate synthetase I (CPS I)** deficiency, which leads to **hyperammonemia** due to impaired urea cycle function.
- The urea cycle is responsible for excreting **amino groups** as urea; one of the key molecules directly incorporated into the urea molecule is **aspartate**, which donates an amino group to form **argininosuccinate**.
*N-acetylglutamate*
- **N-acetylglutamate** is an essential activator of **carbamoyl phosphate synthetase I (CPS I)**, the enzyme deficient in this patient.
- While crucial for the urea cycle's regulation, it is an **allosteric activator** rather than a direct substrate for the synthesis of molecules needed for amino group excretion.
*Homocysteine*
- **Homocysteine** is an intermediate in **methionine metabolism** and is primarily associated with cardiovascular disease and neurological issues when elevated.
- It plays no direct role as a substrate in the urea cycle for the excretion of amino groups.
*Phenylalanine*
- **Phenylalanine** is an **essential amino acid** that is a precursor to tyrosine and neurotransmitters.
- Its metabolism is separate from the urea cycle, and it is not a direct substrate for ammonia excretion in this pathway.
*Valine*
- **Valine** is a **branched-chain amino acid (BCAA)** primarily catabolized in muscles and used for energy.
- It is not a direct substrate in the urea cycle, which processes nitrogen from various amino acids into urea for excretion.
Urea cycle disorders US Medical PG Question 10: A 4-day-old boy is brought to the physician because of somnolence, poor feeding, and vomiting after his first few breast feedings. He appears lethargic. His respiratory rate is 73/min. Serum ammonia is markedly increased. Genetic analysis shows deficiency in N-acetylglutamate synthase. The activity of which of the following enzymes is most likely directly affected by this genetic defect?
- A. Ornithine translocase
- B. Carbamoyl phosphate synthetase I (Correct Answer)
- C. Argininosuccinase
- D. Argininosuccinate synthetase
- E. Arginase
Urea cycle disorders Explanation: ***Carbamoyl phosphate synthetase I***
- **N-acetylglutamate** (NAG) is an essential allosteric activator of **carbamoyl phosphate synthetase I (CPS I)**, the rate-limiting enzyme of the urea cycle.
- A deficiency in **N-acetylglutamate synthase** directly leads to a lack of NAG, significantly impairing CPS I activity and causing severe hyperammonemia.
*Ornithine translocase*
- This enzyme is responsible for transporting **ornithine** into the mitochondria for the urea cycle.
- While a defect in **ornithine translocase** also causes hyperammonemia, it is due to accumulation of ornithine and upstream substrates, not a defect in N-acetylglutamate synthase.
*Argininosuccinase*
- Also known as **argininosuccinate lyase**, this enzyme cleaves argininosuccinate into arginine and fumarate.
- A deficiency would lead to accumulation of **argininosuccinate**, and while it is a urea cycle disorder, it is not directly affected by N-acetylglutamate synthase deficiency.
*Argininosuccinate synthetase*
- This enzyme catalyzes the condensation of **citrulline** and **aspartate** to form argininosuccinate.
- A defect in **argininosuccinate synthetase** causes citrullinemia but is not directly regulated by N-acetylglutamate.
*Arginase*
- **Arginase** is the final enzyme in the urea cycle, hydrolyzing arginine to form urea and ornithine.
- A deficiency would lead to hyperargininemia, which typically presents later in childhood and is not directly affected by N-acetylglutamate.
More Urea cycle disorders US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
